Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.
about
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?Immunotherapy for lung cancerRegulation of Natural Killer Cell Function by STAT3Cancer stem cells and immunoresistance: clinical implications and solutionsALK inhibitors in non-small cell lung cancer: the latest evidence and developmentsNovel therapies in small cell lung cancerImmune Checkpoint Modulation in Colorectal Cancer: What's New and What to ExpectRadiation meets immunotherapy - a perfect match in the era of combination therapy?CADM1 inhibits squamous cell carcinoma progression by reducing STAT3 activity.Immune Checkpoint in Glioblastoma: Promising and ChallengingImmunotherapy at large: Balancing tumor immunity and inflammatory pathologyImmune checkpoint inhibitors in NSCLC.Nivolumab in NSCLC: latest evidence and clinical potentialTargeting precision medicine toxicity: recent developments.Microbiota modulation of myeloid cells in cancer therapyThe role of the microbiota in inflammation, carcinogenesis, and cancer therapy.Combination of Id2 Knockdown Whole Tumor Cells and Checkpoint Blockade: A Potent Vaccine Strategy in a Mouse Neuroblastoma Model.Cancer Immunity: Lessons From Infectious DiseasesPhase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.Several immune escape patterns in non-Hodgkin's lymphomas.PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.Tracheal squamous cell carcinoma (SCC) metastatic to the skin in a patient on a checkpoint inhibitorStereotactic radiation therapy combined with immunotherapy: augmenting the role of radiation in local and systemic treatment.Small Cell Lung Cancer: Can Recent Advances in Biology and Molecular Biology Be Translated into Improved Outcomes?CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer.Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy.Whole-exome sequencing predicted cancer epitope trees of 23 early cervical cancers in Chinese women.Checkpoint inhibitors in immunotherapy of ovarian cancer.Low immunogenicity in non-small cell lung cancer; do new developments and novel treatments have a role?Potential paraneoplastic syndromes and selected autoimmune conditions in patients with non-small cell lung cancer and small cell lung cancer: A population-based cohort study.Assays for predicting and monitoring responses to lung cancer immunotherapy.Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights.Emerging role of nivolumab in the management of patients with non-small-cell lung cancer: current data and future perspectives.Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer.An Enzyme-Directed Imidazoquinoline for Cancer Immunotherapy.Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.Specific antitumour immunity of HIFU-activated cytotoxic T lymphocytes after adoptive transfusion in tumour-bearing mice.Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.Targeting PD-L1 for non-small-cell lung cancer.Immunotherapy in Lung Cancer.
P2860
Q26741101-BFCF9C9C-9571-4AA6-92ED-F2F01EE7AA29Q26751254-7A8486BC-9A83-49D7-BF5C-6515C3385F55Q26752551-5EE3757C-5A73-4AE0-9151-CF05448E968FQ26769757-69A846E8-67D9-4069-A9C9-66C5221AB39AQ26769879-2F28DBD7-B5B1-4C3D-882A-18A0E3C78707Q26775390-557FC8E2-F7EC-4A09-B546-FDC02BB88BF0Q26775578-FDAD595D-51D4-47D0-9C6B-27B08D5D5DE0Q27005913-C2B2EF76-064A-4FD8-A9DF-83D308DD4A74Q27323547-3D063FF6-5188-4034-852D-E7B6621FFCB8Q33650058-9127E56F-935C-46A4-8CE2-FA9D05CBA743Q33856217-304BB1FD-EBA3-4297-B8D6-4B6070171165Q34437570-29741AA6-DD7A-48A0-8F47-3EB4F34A72CFQ34466452-404E1702-C592-465D-A280-2E2F89FB88FBQ35019470-3155D09E-2E45-4BD3-BE7B-47136203BBC2Q35073092-ADD99493-F9A3-4D77-BF7C-17C5EB92DDDBQ35346303-AED62949-AE20-4321-B7DA-F2C5FCD78396Q35664913-77718CE4-620D-477F-8901-61AAA14875FFQ35676186-F99C72D0-A81A-4B38-A1D5-865C20AAB850Q35817265-620EAFDF-CD15-4D39-B4FF-4A89AC1A77A5Q36060357-747599B4-4821-48E4-B1AA-89B0C46DECE9Q36561681-6625BC8E-D61A-4F62-B461-D51AA64BB39EQ36733411-C34EACED-98AA-465E-9B34-5D5BBA7EF59BQ36746004-29404E3A-2629-4BFE-96E3-D61EA73C9CA1Q36811784-52D7C19B-264A-4E5A-B372-FF3F4236DA98Q37042256-B056E41B-7A2D-49D7-8EEA-C9EFE2055CB2Q37462524-7DA244A0-2506-468E-8C0C-BC180FD475CFQ37609228-1F79DB07-0FFE-40A8-9B1D-D0F099058DE9Q38269568-CE103D1D-DAF2-444E-82AD-BC9FDEF129F4Q38366141-F958CEF1-2620-4296-8557-BE5F8CB2A8C4Q38399431-8D02AB83-78A1-4493-A951-95E6BA379105Q38547391-8DF07FC4-C5A0-493D-B27F-C6A8B9B34A91Q38549542-2C04DCB1-E7AA-476E-A189-6EA16DFD240FQ38645803-6951E0AA-79C9-48C5-873F-B9214C14BB96Q38739807-1D885BEE-0B03-4747-888A-6F1FD8A990EDQ38741706-12418CEC-80E6-42DC-970E-6E74F7FACFDCQ38806038-604E826B-9AA7-4A4C-8606-C46607CE8AE7Q38808691-2B61346A-B023-4ED0-A8D9-B0820E9C65A1Q38830398-6A42B9D5-EBFB-4645-A7DC-66E9216CEAB8Q38838651-EC72C063-8296-4EA7-A67E-CCC2976DECE2Q38930370-B9ADA30D-B2FD-4A6E-AC09-02405873F394
P2860
Immune checkpoint inhibitors: making immunotherapy a reality for the treatment of lung cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Immune checkpoint inhibitors: ...... the treatment of lung cancer.
@en
type
label
Immune checkpoint inhibitors: ...... the treatment of lung cancer.
@en
prefLabel
Immune checkpoint inhibitors: ...... the treatment of lung cancer.
@en
P2860
P1476
Immune checkpoint inhibitors: ...... the treatment of lung cancer.
@en
P2093
Drew M Pardoll
Julie R Brahmer
P2860
P356
10.1158/2326-6066.CIR-13-0078
P577
2013-07-22T00:00:00Z